Isotopia Launches Isoprotrace® in the UK to Advance Prostate Cancer Imaging

Isotopia Molecular Imaging has officially introduced Isoprotrace®, its cutting-edge Gallium-68 Gozetotide radiolabelling kit, to the UK market. This launch marks a significant step in the company’s global effort to enhance access to high-quality diagnostic tools for prostate cancer.

Isoprotrace® is a ready-to-use, multi-dose kit containing PSMA-11 (Gozetotide), engineered to streamline the preparation of Gallium-68 Gozetotide for intravenous use. It plays a crucial role in improving the accuracy of prostate cancer detection and supporting more effective treatment planning.

In collaboration with Light Medical, Isotopia ensures that Isoprotrace® will be widely distributed across the United Kingdom. This partnership is designed to support healthcare professionals with reliable access to advanced diagnostic technology for managing prostate cancer.

Tzachi Levy, General Manager of Isotopia’s aseptic manufacturing facility, emphasized the significance of the launch:
"With the increasing demand for precision imaging in prostate cancer care, Isoprotrace® offers healthcare professionals an essential tool to improve diagnostic accuracy and enhance treatment outcomes."

Mark Goodwin, Director at Light Medical, commented on the collaboration:
"We are honored to collaborate with Isotopia in introducing Isoprotrace® to the UK market. This launch marks a vital step forward in combating prostate cancer, and we are committed to ensuring widespread availability of this innovative diagnostic kit for healthcare providers nationwide."

Isotopia remains focused on maintaining a resilient supply chain to ensure uninterrupted availability of this essential diagnostic product both in the UK and globally.

For full product details and availability, visit: https://isotopia-global.com/isoprotrace/